RecruitingACTRN12618000165280

Smoking cessation and effects of cigarette smoking on cure and side effects of treatment in patients with cancer in the head and neck region.

Smoking and its impact on treatment outcome and survival in head and neck cancer patients: a longitudinal observational study


Sponsor

MADHAVI CHILKURI

Enrollment

156 participants

Start Date

Feb 6, 2021

Study Type

Observational

Conditions

Summary

This observational study will evaluate smoking cessation and its impact on treatment outcome and survival in patients with head and neck cancer. Who is it for? You may be eligible to join this study if you are aged 18 years or older and have a confirmed diagnosis of Stage I-IV squamous cell carcinoma of the oral cavity, pharynx, larynx, nasal cavity or paranasal sinuses, for which you are deemed suitable for curative treatment at Townsville Cancer Centre. Study details Participants will undergo cancer treatment and may participate in the existing smoking cessation program as per standard of care at Townsville Cancer Centre. They will then be followed up at 3 months, 6 months, 9 months, 1 year, 2 years, 3 years and 5 years post treatment to evaluate a number of outcomes, including smoking cessation rate among smokers, treatment toxicities, and clinical response to treatment. It is hoped that the results of this study will help inform patients and health care providers and facilitate improvement in quality of care and patient compliance leading to improved disease control, survival and quality of life.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at how quitting smoking affects the outcomes of treatment for head and neck cancer. Head and neck cancers include cancers of the mouth, throat, voice box, and nasal passages. Researchers will track whether patients who stop smoking during or after treatment do better than those who continue — including how well the treatment works, side effects, and survival rates. Participants will be followed up for up to 5 years after treatment. You may be eligible if: - You are 18 years or older - You have been diagnosed with squamous cell carcinoma of the oral cavity, pharynx, larynx, nasal cavity, or paranasal sinuses (Stage I–IV, no distant spread) - You are receiving curative treatment at Townsville Cancer Centre - You are in good enough health to undergo curative treatment (ECOG Performance Status 0–1) - You are of any smoking status (smoker or non-smoker) You may NOT be eligible if: - Your cancer type is not squamous cell carcinoma - Your cancer has spread to distant parts of the body (metastatic) - You are pregnant - Your cancer has come back (recurrent disease) - You have previously had radiation therapy to the head and neck region Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This study will evaluate the efficacy of the existing smoking cessation program at Townsville Cancer Centre, its impact on smoking behaviour and the effect of smoking cessation on patient outcomes. Th

This study will evaluate the efficacy of the existing smoking cessation program at Townsville Cancer Centre, its impact on smoking behaviour and the effect of smoking cessation on patient outcomes. The smoking cessation strategy includes assessment of smoking status, carbon monoxide breath testing, advice and counselling, pharmacotherapy with Nicotine patches, and referral to GP and/or Quitline. This strategy occurs at diagnosis and continues with ongoing counselling and pharmacotherapy during follow up visits. The results of this study will help inform patients and health care providers and facilitate improvement in quality of care and patient compliance leading to improved disease control, survival and quality of life. Patients will be followed up for 5 years from start of treatment.


Locations(1)

The Townsville Hospital - Douglas

QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12618000165280


Related Trials